Stocks and Investing
Stocks and Investing
Mon, February 26, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, February 23, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Stephen Willey Maintained (BMRN) at Strong Buy with Decreased Target to $102 on, Feb 23rd, 2018
Stephen Willey of Stifel, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $105 to $102 on, Feb 23rd, 2018.
Stephen has made no other calls on BMRN in the last 4 months.
There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, 0 agree with Stephen's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Stephen
- Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $129 on, Wednesday, January 24th, 2018
- Liana Moussatos of "Wedbush" Upgraded from Hold to Buy on, Thursday, December 14th, 2017